Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givastomig - I-MAB Biopharma

Next Previous
Drug Profile

Givastomig - I-MAB Biopharma

Alternative Names: ABL-111; CD4B; Giva; TJ-033721; TJ-CD4B; TJ-CLDN4B

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Adenocarcinoma; Gastric cancer; Pancreatic cancer; Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 08 Sep 2025 I-MAB Biopharma plans a phase Ib trial of givastomig for Biliary tract cancer (First-line therapy, Combination therapy)
  • 08 Sep 2025 I-MAB Biopharma plans investigator initiated trials of givastomig for Solid tumours (Late-stage disease, Neoadjuvant therapy, Combination therapy, First-line therapy)
  • 08 Sep 2025 I-MAB Biopharma plans a phase II trial for Gastric cancer (Combination therapy, First-line therapy, Metastatic disease) in Q1 of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top